AUTHOR AND EDITOR INFORMATION

Section 1 of 11  

• Authors and Editors
• Introduction
• Antibiotics
• Antipsychotics
• Analgesics
• Antivirals
• Medication
• Inpatient Care
• Implementation of Switch Therapy Protocol
• Special Concerns
• References

INTRODUCTION

Section 2 of 11  

• Authors and Editors
• Introduction
• Antibiotics
• Antipsychotics
• Analgesics
• Antivirals
• Medication
• Inpatient Care
• Implementation of Switch Therapy Protocol
• Special Concerns
• References

Switching from intravenous to oral therapy as soon as patients are clinically stable can reduce the length of hospitalization and lower associated costs. While intravenous medications may be more bioavailable and have greater effects, some oral drugs produce serum levels comparable to those of the parenteral form. Medications involved in switch therapy include antibiotics, analgesics, antipsychotics, and antivirals.

Community-acquired pneumonia

One of the most common uses of intravenous-to-oral (IV-to-PO) switch therapy is in the treatment of community-acquired pneumonia (CAP). CAP is most commonly caused by Streptococcus pneumoniae infection. The natural history of CAP is beyond the scope of this article; see Pneumonia, Community-Acquired for more information. In terms of switch therapy, approximately 40-50% of patients admitted for intravenous antibiotics can be switched to oral antibiotics within 2-3 days.

The US Medicare Pneumonia Project database provided evidence that the routine practice of in-hospital observation after the switch from intravenous to oral antibiotics in patients with CAP can be avoided in those who are clinically stable.¹ Explicit physiological criteria must be recorded routinely to serve as a benchmark in order for the switch to be consistently successful.

In 1999, Siegel reported that the treatment of hospitalized patients with uncomplicated CAP is changing to include a brief period of intravenous antibiotics followed by oral therapy.² The Classification of Community-Acquired Pneumonia (CoCAP) is a stratification tool in which patients are categorized as having low-risk pneumonia, unstable pneumonia, or complicated pneumonia. Caregivers can achieve a structure for organizing treatment of patients with CAP by using (1) validated hospital admission criteria, (2) the CoCAP algorithm, and (3) newly evolving criteria for switching patients from intravenous to oral therapy.

Patients with unstable pneumonia can be discharged early if (1) their metabolic problems have reversed and comorbid conditions have stabilized and (2) they have not developed any serious pneumonia-related complications. Prolonged courses of intravenous antibiotic therapy are being replaced with 2- to 3-day courses of intravenous hydration and antibiotics; patients can be switched to oral therapy and can be discharged from the hospital after they tolerate one dose of oral therapy. The vital signs and the WBC count should be monitored, and, provided these parameters are improving (although possibly not normalized), patients can be switched to oral therapy.

Patient treatment guidelines and critical pathways are becoming widespread in disease management, and CAP is one disease in which prospective studies have demonstrated that a reduction in hospital stay is safe and agreeable with patients, caregivers, and administrators. Other treatment protocols are being explored, including a single dose of intravenous antibiotic prior to the oral switch and all-oral regimens using the newer fluoroquinolones. A study by Ramirez et al (2005) showed that the care recommended by national guidelines regarding switching from intravenous to oral therapy was not being appropriately delivered to adults with CAP in all regions of the world.³

Different doctors have different approaches to switch therapy. Inpatients with CAP treated by hospital clinicians had a shorter adjusted length of stay than those treated by primary care physicians, primarily because of earlier recognition of stability and more rapid conversion from intravenous to oral antibiotics. Adjusted costs were likewise reduced. However, patients treated by hospital clinicians were more often discharged with an unstable clinical variable. Other than earlier switching to oral antibiotics, less use of clindamycin and ceftazidime, and fewer consultations with infectious disease specialists, the care processes of hospital clinicians were similar to those of primary care physicians.⁴

In 2004, Wawruch et al reported on an evaluation of a group of patients selected out of 2870 patients who were hospitalized at the Clinic of Geriatric Medicine at Comenius University in Bratislava from January 1, 1999, to December 31, 2001. In their retrospective study, Wawruch et al analyzed 96 patients with CAP who were successfully treated with antibiotics. Forty-three patients received intravenous antibiotics, and 53 received IV-to-PO switch therapy (ie, intravenous administration was used at the beginning and oral administration was used when their conditions improved).⁵

According to the cost-effectiveness coefficient, the switch therapy was significantly less expensive in all evaluated antibiotics (except pefloxacin) compared with intravenous administration. For ampicillin-sulbactam, the coefficients were 93.9 versus 168.1, 90 versus 123.3 for cefuroxime, 74 versus 116.3 for amoxicillin-clavulanate, and 31.7 versus 54.1 for ciprofloxacin. Wawruch et al found that timely switching from intravenous to oral administration of antibiotics in suitable patients is an effective way to save financial resources.⁵

Oosterheert et al (2006), based on a study of 302 patients, found that early switch from intravenous to oral antibiotics in patients with severe CAP is safe and decreases the hospital stay by 2 days.⁶

Other uses of switch therapy can include the treatment of spontaneous bacterial peritonitis. A more cost-effective switch therapy in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis who are not receiving prophylaxis with quinolones involves the use of a cephalosporin rather than intravenous ceftazidime.⁹

ANTIBIOTICS

Section 3 of 11  

• Authors and Editors
• Introduction
• Antibiotics
• Antipsychotics
• Analgesics
• Antivirals
• Medication
• Inpatient Care
• Implementation of Switch Therapy Protocol
• Special Concerns
• References

Switch therapy is possible with various oral antibiotics. Antibiotics ideal for intravenous-to-oral (IV-to-PO) switch programs include chloramphenicol, clindamycin, metronidazole, trimethoprim-sulfamethoxazole, fluconazole, itraconazole, voriconazole, doxycycline, minocycline, levofloxacin, moxifloxacin, and linezolid.¹⁰

Sequential antibiotic therapy ensures an early switch to the oral route when a patient is clinically stable. This increasingly used strategy is safe and improves the quality and cost-effectiveness of health care. Timely and appropriate switch therapy must be underpinned by clear guidelines and supported by a multidisciplinary team. According to some authorities, approximately 40% of patients starting on intravenous antibiotics are candidates for a switch to oral antibiotics after 2-3 days of therapy.

In 2004, Vogtlander et al, at the Department of General Internal Medicine, University Medical Center Nijmegen, in the Netherlands, involved the departments of internal medicine, surgery, and neurology and the emergency department at a tertiary referral university medical center in a study of all consecutive patients receiving therapeutic antibiotics. Dosages, timing of first doses, dosing intervals, administration routes, and adjustment of the chosen drug to clinical data were investigated. After the preintervention period, barriers to change were identified, followed by specific interventions and a postintervention measurement. In the preintervention and postintervention periods, 247 and 250 patients were enrolled, receiving 563 and 598 antibiotic prescriptions, respectively.¹¹

The mean time from the order to first dose at the wards improved from 2.7 to 1.7 hours in potentially severe cases (P = .003). Dosage adjustment per renal function remained unchanged at 45% versus 52% (P = .09) of cases when necessary. Switching of therapy from an intravenous route to an oral route improved from 46% to 62% (P = .03) and was performed a mean of 1.6 days earlier (P = .002). Streamlining was performed correctly in most cases; thus, no interventions were necessary. Timing of antibiotic therapy and switch therapy may be improved with a combination of interventions. Other strategies are needed to improve the poor adjustment of dosing per renal function. In this study, streamlining was already correct in most cases.¹¹

Fluoroquinolones

Levofloxacin and ofloxacin

Fluoroquinolones are suitable for switch therapy. The intravenous and oral formulations of levofloxacin have same-dose bioequivalence, allowing for switch or step-down therapy from parenteral to oral formulations of the same agent at the same dose. In the late 1990s, ofloxacin was also used for switch therapy, but its role is unclear in switch therapy because it is a twice-a-day medication, whereas levofloxacin is a once-a-day medication. Fluoroquinolones should not be used in children because of a possible adverse effect on cartilage.

Levofloxacin provides almost complete (>99%) oral bioavailability, suggesting that oral administration may provide exposure that is comparable to that of the intravenous regimen. The overall clinical success rate in such a switch is 94.1%. In several randomized controlled trials, 5-14 days of treatment with intravenous and/or oral levofloxacin proved to be an effective therapy for patients with upper and lower respiratory tract infections. In patients with mild-to-severe community-acquired pneumonia (CAP), intravenous and/or oral levofloxacin at a dose of 500 mg once or twice daily was as effective as clarithromycin, azithromycin, and amoxicillin/clavulanic acid. Overall, clinical response rates with levofloxacin were 86-95% versus 88-96% with comparator agents; bacteriological response rates were 88-95% and 86-98%, respectively.

In 2005, Pablos et al reported on a study of the consumption of quinolones (eg, ofloxacin, levofloxacin, ciprofloxacin) 6 months before and after the implementation of a sequential therapy program in hospitalized patients. A program was calculated for each antibiotic, in its oral and intravenous forms, in "defined daily dose/100 stays per day" and in economic terms (drug acquisition cost). At the beginning of the program, ofloxacin was replaced by levofloxacin and, because their clinical uses are similar, the consumption of both drugs was compared during the period.¹²

In economic terms, the consumption of intravenous quinolones decreased 60%, whereas the consumption of oral quinolones increased 66%. In "defined daily dose/100 stays per day," consumption of intravenous forms decreased 53% and consumption of oral forms increased 36%. Pablos et al focused on quinolones and their use in implementing a sequential therapy program based on promoting an early switch from an intravenous regimen to an oral regimen. They proved the program's capacity to alter the use profile of these antibiotics. During the period under consideration, the program achieved a global drug savings of $41,420 for the hospital.¹²

Ciprofloxacin

Ciprofloxacin also has a role in IV-to-PO switch therapy. Giamarellou and colleagues demonstrated that high-dose ciprofloxacin administered intravenously for at least 3 days and then orally is therapeutically equivalent to the routine regimen of intravenous ceftazidime plus amikacin, even in febrile patients with severe neutropenia (ie, polymorphonuclear leukocyte count, <100/µL).¹³

Solomkin and colleagues studied patients with complicated intra-abdominal infections, who were randomized to receive either (1) intravenous ciprofloxacin plus metronidazole or intravenous imipenem throughout their treatment course or (2) intravenous ciprofloxacin plus metronidazole and treatment with oral ciprofloxacin plus metronidazole when oral feeding was resumed. The study demonstrated statistical equivalence between intravenous ciprofloxacin plus metronidazole and intravenous imipenem in both the intent-to-treat and valid populations. Conversion to oral therapy with intravenous ciprofloxacin plus metronidazole appeared as effective as continued intravenous therapy in patients able to tolerate oral feedings.¹⁴

Moxifloxacin

In 2003, a trial reported by Drummond et al compared sequential intravenous/oral monotherapy with moxifloxacin (400 mg/d) to intravenous/oral co-amoxiclav (1.2 g IV/625 mg PO tid) with or without clarithromycin (500 mg bid) for 7-14 days in hospitalized patients with CAP and found that intravenous/oral monotherapy with moxifloxacin shows clinical benefits, including increased speed of response, and is cost-effective compared with intravenous/oral co-amoxiclav with or without clarithromycin.¹⁵

Similarly, in 2002, Finch et al noted that monotherapy with moxifloxacin is superior to a standard combination regimen of a beta-lactam and a beta-lactamase inhibitor (co-amoxiclav) with or without a macrolide (clarithromycin) in the treatment of patients with CAP admitted to a hospital.¹⁶

Specifically, Finch et al noted the superiority of moxifloxacin irrespective of the pneumonia severity and regardless of whether the combination therapy included a macrolide. The time to resolution of fever was also statistically significantly faster in patients who received moxifloxacin (median time, 2 vs 3 d), and the duration of hospital admission was approximately 1 day less among patients who received moxifloxacin. The treatment was converted to oral therapy immediately after the initial mandatory 3-day period of intravenous administration for a larger proportion of patients in the moxifloxacin group than patients in the comparator group (151 [50.2%] vs 57 [17.8%] patients). Fewer deaths (9 [3%] vs 17 [5.3%]) and fewer serious adverse events (38 [12.6%] vs 53 [16.5%]) were reported in the moxifloxacin group than in the comparator group.¹⁶

Cephalosporins

Similar switches can be effective with cephalosporins. Validated treatment algorithms, such as the Classification of Community-Acquired Pneumonia (CoCAP), now enable decisions concerning which patients with CAP require hospitalization and which patients will benefit from early switch therapy. Generally, unstable patients with CAP are suitable candidates for early switch therapy, which consists of rapid initiation of 1-2 days of intravenous therapy followed by 5 days of oral therapy, with early hospital discharge after the administration of 1-2 doses of oral antibiotic.

Cefuroxime, cefuroxime axetil, and cefetamet pivoxil

Studies of intravenous cefuroxime followed by oral cefuroxime axetil suggest this regimen is both effective and well-tolerated as rapid switch therapy and has the potential to reduce overall health care costs and improve patient satisfaction. Specifically, Van den Brande and colleagues noted that intravenous cefuroxime twice daily followed by oral cefuroxime axetil is a simple and effective sequential therapy regimen for the treatment of CAP.¹⁷

Hamilton-Miller found that switch therapy to cefixime after 2-3 days used to treat serious infections resulted in excellent clinical outcomes.¹⁸ Similarly, Dagan and colleagues found that 1 or 2 days' treatment with parenteral ceftriaxone before switching to oral cefetamet pivoxil was safe and effective in the treatment of childhood pneumonia.¹⁹ This suggests that parenteral-to-oral switch therapy is a feasible treatment option in the treatment of serious pediatric CAP.

Ceftriaxone and ceftibuten

Fernandez and San Martin studied 40 patients admitted to the hospital because of CAP. Initially, these patients were treated with intravenous ceftriaxone (1 g/d) and showed clinical improvement after 3 days of therapy. They were randomly assigned to continue intravenous ceftriaxone therapy for a total of 10 days or to switch to ceftibuten (400 mg/d) for 7 days. Twenty-one of the patients continued intravenous treatment, and 19 were switched to ceftibuten. In terms of clinical cure, radiological improvement, and normalization of WBC count, no differences were noted between the 2 groups.²⁰ These findings support the viability of switch therapy in this context.

Macrolides

Azithromycin

The macrolide azithromycin appears to be superior to the cephalosporin cefuroxime in intravenous therapy and a subsequent switch to oral therapy. This was shown in a cost-effectiveness analysis of IV-to-PO switch regimens of azithromycin versus cefuroxime with or without erythromycin in the treatment of patients hospitalized with CAP.

Clarithromycin

Clarithromycin can also be used to in an IV-to-PO switch regimen. In 2000, Parola et al reported on 290 patients with CAP who were given clarithromycin at 500 mg twice daily, first given intravenously in 250 or 500 mL of saline solution and then switched after 4-5 days to the same dose given orally. Within 10-15 days, 261 (90%) of 290 patients improved clinically and radiologically.²¹

Other Antibiotics

Clindamycin

Martinez and associates found that switch therapy can be used when administering clindamycin.²² Specifically, a multicenter, prospective, controlled study compared the clinical efficacy, safety, and economic impact of pharmacist intervention to promote sequential IV-to-PO clindamycin conversion. Clindamycin was prescribed for respiratory tract infections in 38.9% of patients and for prophylaxis in surgery in 25.4% (71% were contaminated during surgery). A total of 473 patients receiving intravenous clindamycin for at least 72 hours were included in the study. Two groups were established. Those in the intervention group (204 patients) were given an informative sheet recommending the sequential treatment, and the other group consisted of 269 control patients. Outcomes appeared similar.

Ertapenem

The efficacy and safety of intravenous ertapenem (1 g/d) with the option to switch to an oral agent for treatment of adults with complicated urinary tract infections were compared with those of intravenous ceftriaxone (1 g/d) with the same oral switch option in a multicenter, double-blinded, prospective randomized study. The frequency and severity of drug-related adverse events were generally similar in both treatment groups. In this study, ertapenem was as effective as ceftriaxone for the initial treatment of complicated urinary tract infections in adults, was generally well tolerated, and had a similar overall safety profile.²³

Linezolid

In 2003, Li et al noted that intravenous linezolid can be followed by oral linezolid; these regimens were found to shorten hospital stays.²⁴ The exact timing of the switch depends on the clinical condition of the patient; oral and intravenous linezolid are relatively similar in effect. Linezolid is available in intravenous, film-coated tablet, and oral suspension forms. Linezolid can be assayed in serum and body fluids and has good bioavailability, with a maximum blood concentration at 0.5-2 hours.

Metronidazole

Metronidazole can be part of regimens for switching patients from intravenous to oral therapy. Treatment between prolonged intravenous therapy and intravenous therapy followed by conversion to oral antibiotic therapy is equivalent in children with perforated appendicitis. Similarly, a study noted 8 patients with brain abscesses who refused prolonged hospitalization and were treated with a short course (6-12 d) of intravenous antibiotics followed by prolonged treatment (15-19 wk) with an oral antibiotic regimen consisting of metronidazole, ciprofloxacin, and amoxicillin. All patients responded favorably based on clinical findings and imaging studies.

In 2003, Starakis et al compared the efficacy and safety of sequential intravenous/oral ciprofloxacin plus intravenous/oral metronidazole with that of intravenous ceftriaxone plus intravenous/oral metronidazole in the treatment of complicated intra-abdominal infections in 135 patients. Conversion to oral therapy with ciprofloxacin/metronidazole was as effective as continued intravenous therapy with ceftriaxone and oral metronidazole in patients who were able to tolerate oral feeding.²⁵

Similarly, in 1996, Solomkin et al reported a study in which patients were randomized to either (1) ciprofloxacin plus metronidazole intravenously or imipenem intravenously throughout their treatment course or (2) ciprofloxacin plus metronidazole intravenously and treatment with oral ciprofloxacin plus metronidazole when oral feeding was resumed, with equal outcomes.¹⁴

Trimethoprim-sulfamethoxazole

Trimethoprim-sulfamethoxazole (Bactrim) can also be used as part of IV-to-PO switch regimens. In 2002, Gollin et al reported on a study of 80 children who underwent appendectomy for perforated appendicitis. The children were safely discharged home on a 7-day course of oral trimethoprim-sulfamethoxazole and metronidazole when enteral intake was tolerated, regardless of fever or leukocytosis.²⁶

Antifungals

Itraconazole and fluconazole

The efficacy and safety of intravenous and oral itraconazole and intravenous and oral fluconazole for long-term prophylaxis of fungal infections in transplantation patients have been established; itraconazole is better tolerated. Generally, in patients who can take oral medications, itraconazole and fluconazole can be given orally with no adverse effects or effect on outcomes. Similarly, in 2002, Purkins et al noted that switching from intravenous to oral voriconazole can be effectively achieved.²⁷

Specifically, in 2002, Winston and Busuttil reported a study in which adult liver transplant recipients were randomized to receive either an oral itraconazole solution (200 mg q12h) or intravenous/oral fluconazole (400 mg/d). Each study drug was started immediately before the transplantation surgery and continued for 10 weeks after transplantation. Patients were evaluated for fungal colonization, proven invasive or superficial fungal infection, drug-related adverse effects, and death. Results were similar.²⁸

ANTIPSYCHOTICS

Section 4 of 11  

• Authors and Editors
• Introduction
• Antibiotics
• Antipsychotics
• Analgesics
• Antivirals
• Medication
• Inpatient Care
• Implementation of Switch Therapy Protocol
• Special Concerns
• References

Citalopram

Recently, the selective serotonin reuptake inhibitor citalopram has been administered as an intravenous infusion to patients with severe depression. The results from both open and double-blinded clinical studies with intravenous citalopram suggest that it is an effective and well-tolerated treatment for depression. Moreover, when infusion treatment is initiated and continued orally, citalopram is at least as effective as clomipramine, doxepin, and viloxazine. As with oral treatment, adverse events are mild to moderate in severity, and 50% of patients report no adverse events.

The high bioavailability of citalopram indicates that the switch from intravenous to oral citalopram prevents a deterioration of symptoms because plasma drug concentrations are maintained. Thus, citalopram, the only selective serotonin reuptake inhibitor available as an intravenous formulation, may be a useful addition in the treatment of patients with severe depression who may benefit from more intensive therapy.²⁹

Doxepin

In 1997, Adler et al conducted a randomized, double-blinded, placebo-controlled study on doxepin to evaluate the effect of a switch from parenteral to oral administration upon symptoms of endogenous depression. They tested the hypothesis that the treatment response significantly worsens during the switch and concluded that this hypothesis must be rejected based on objective and subjective psychometric test findings. In fact, they noted continuous improvement. Preconditions included selection of patients with typical endogenous depression and maintenance of at least constant plasma levels of the active antidepressants.³⁰

In patients younger than 65 years, doxepin plasma levels can be kept constant by switching in a ratio of 125 mg intravenous to 250 mg oral. Individual case studies indicated that declining progress after switching was correlated with a decreasing plasma level of the active drug. An already-low plasma level during the infusion period, insufficient response, and questionable compliance with the oral medication were associated factors. Owing to large (by a factor of 10) interindividual differences of plasma levels, measurements before and after switching were required.

ANALGESICS

Section 5 of 11  

• Authors and Editors
• Introduction
• Antibiotics
• Antipsychotics
• Analgesics
• Antivirals
• Medication
• Inpatient Care
• Implementation of Switch Therapy Protocol
• Special Concerns
• References

Acetaminophen

Promptly switching intravenous acetaminophen to oral acetaminophen is possible in patients with severe pain outbreaks if certain steps have been taken, including the establishment of a local consensus process, presentation of a short educational program, display of posters in all nurses' offices, and feedback regarding the practice 6 months after implementation of guidelines.

ANTIVIRALS

Section 6 of 11  

• Authors and Editors
• Introduction
• Antibiotics
• Antipsychotics
• Analgesics
• Antivirals
• Medication
• Inpatient Care
• Implementation of Switch Therapy Protocol
• Special Concerns
• References

Acyclovir

Carcao and colleagues noted that immunocompromised children are at risk for disseminated varicella infections and that standard treatment involves hospitalization and intravenous acyclovir for 7-10 days. Carcao et al undertook a pilot study to assess the safety and efficacy of an alternative approach that involved a combination of intravenous followed by oral acyclovir in a cohort of immunocompromised children. Specifically, the cohort consisted of 26 immunocompromised children aged 1.5-12.7 years (mean age, 6.3 y).³¹

Therapy was commenced with intravenous acyclovir (1500 mg/m²/d in 3 divided doses). Concurrent treatment included holding or reducing immunosuppressive therapy (by 50%) and administering varicella-zoster immunoglobulin in 11 (69%) of 16 patients in whom exposure to chickenpox was recognized. Patients were eligible to switch to oral therapy after receiving a minimum of 48 hours of intravenous acyclovir therapy, provided they were afebrile, had no new lesions for 24 hours, had no internal organ involvement, and were able to tolerate oral medications.³¹

Patients were observed in the hospital for another 24 hours and were then discharged provided they remained well. Oral acyclovir was continued for a total of 7-10 days (intravenous plus oral). Carcao et al found that 25 of the 26 patients were successfully switched from intravenous to oral administration after 4.1 (mean) ± 1.2 days (standard deviation) (range, 2.3-6 d). Children had fever for a mean of 2 ± 1.6 days (range, 0-5 d) and developed new lesions for 2.9 ± 0.7 days (range, 2-4 d).³¹

Disease resolved in all 25 patients who switched to oral therapy, and no patient required resumption of intravenous therapy. Carcao and associates concluded that the sequential use of intravenous acyclovir followed by oral acyclovir is feasible in the treatment of varicella infection in immunocompromised children and results in a reduced duration of intravenous therapy and hospitalization.³¹

Famciclovir and valacyclovir

MEDICATION

Section 7 of 11  

• Authors and Editors
• Introduction
• Antibiotics
• Antipsychotics
• Analgesics
• Antivirals
• Medication
• Inpatient Care
• Implementation of Switch Therapy Protocol
• Special Concerns
• References

For community-acquired pneumonia (CAP), both fluoroquinolones and cephalosporins can be switched from intravenous to oral administration. The same may be true for many other disease processes, but each must be specifically evaluated, which is beyond the scope of this article.

Drug Category: Antibiotics

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Drug Category: Tricyclic antidepressants

This is a complex group of drugs that have central and peripheral anticholinergic effects and sedative effects. They block active reuptake of norepinephrine and serotonin.

Drug Category: Selective serotonin reuptake inhibitors

These agents specifically inhibit presynaptic reuptake of serotonin but not noradrenaline.

Drug Category: Antivirals

Nucleoside analogs are initially phosphorylated by viral thymidine kinase to eventually form a nucleoside triphosphate. These molecules inhibit HSV polymerase with 30-50 times the potency of human alpha-DNA polymerase.

INPATIENT CARE

Section 8 of 11  

• Authors and Editors
• Introduction
• Antibiotics
• Antipsychotics
• Analgesics
• Antivirals
• Medication
• Inpatient Care
• Implementation of Switch Therapy Protocol
• Special Concerns
• References

Inpatients with nonsevere community-acquired pneumonia (CAP) can be effectively and safely treated with oral antimicrobials from the time of admission, whereas those with severe pneumonia can be treated with early switch therapy. Once a hospitalized patient with CAP is clinically stable, switching from intravenous to oral antibiotics, even if the bacteremia was initially documented to be caused by S pneumoniae, is safe. 

Numerous factors must be weighed before switching hospitalized patients from intravenous to oral antibiotics. In a study by Halm et al, the following factors were rated as very important to the antibiotic conversion decision:³²

• Absence of suppurative infection (93%)
• Ability to maintain oral intake (79%)
• Respiratory rate at baseline (64%)
• No positive blood culture findings (63%)
• Normal temperature (62%)
• Oxygenation at baseline (55%)
• Mental status at baseline (50%)

Fifty-eight percent of physicians believed that "patients should be afebrile for 24 hours before conversion to oral antibiotics," and 19% said "patients should receive a standard duration of intravenous antibiotics." The median thresholds at which physicians believed a typical patient could be converted to oral therapy were as follows:³²

• Temperature of less than or equal to 100°F (37.8°C)
• Respiratory rate of less than or equal to 20 breaths per minute
• Heart rate of less than or equal to 100 beats per minute
• Systolic blood pressure of 100 mm Hg or higher
• Room air oxygen saturation of 90% or higher

In univariate analyses, pulmonary and infectious disease physicians were the most predisposed toward early conversion to oral antibiotics, and other medical specialists were the least predisposed, with generalists being intermediate (P <.019). In multivariate analyses, practice beliefs were associated with age, inpatient care activities, attitudes about guidelines, and agreeableness on a personality inventory scale. In summary, physicians believed that patients could be switched to oral antibiotics once vital signs and mental status had stabilized and oral intake was possible. However, antibiotic practice beliefs varied considerably.³²

Regarding the management of CAP, Ramirez reported in 2001 that switch therapy can reduce costs associated with drug administration and length of hospital stay. He stated that switch therapy can be safely implemented when the following 4 criteria are met: (1) cough and respiratory distress improve, (2) fever abates for at least 8 hours, (3) the WBC count is returning to within the reference range, and (4) the patient can take drugs orally. In prospective clinical studies conducted at his institution, the clinical cure rate with switch therapy was 99% and the mean length of hospital stay was reduced by more than 2 days. Early switch, coupled with hospital discharge, may be possible in nearly half of all patients with CAP. Ramirez concluded that universal use of switch therapy in the United States could result in a total reduction of approximately 440,000 hospital days annually and an overall savings of $400 million.³³

In 1999, Ramirez and colleagues studied early switching to oral antibiotics (within the first 3 d of hospitalization) in 133 patients (67%). Clinical failure was documented in 1 patient. Early switch and early discharge was achieved in 88 patients (44%). The mean length of hospital stay for this group was 3.4 days. The most common reason for prolonged hospitalization after the switch to oral antibiotics was the need for a diagnostic workup. More than 95% of patients were satisfied with the care they had received. Ramirez and colleagues concluded that, based on simple clinical and laboratory criteria, a significant proportion of hospitalized patients with CAP (44%) can be treated with early switch and early discharge. This model did not affect patient outcome, but it did decrease the length of hospitalization and was associated with a high level of patient satisfaction.³⁴

IMPLEMENTATION OF SWITCH THERAPY PROTOCOL

Section 9 of 11  

• Authors and Editors
• Introduction
• Antibiotics
• Antipsychotics
• Analgesics
• Antivirals
• Medication
• Inpatient Care
• Implementation of Switch Therapy Protocol
• Special Concerns
• References

Important questions include how to identify candidates for an early switch and how to effect the IV-to-PO switch. Releasing IV-to-PO switch guidelines alone is not sufficient. Electronic drug-ordering systems have been introduced during the past years, enabling a central computer to provide a daily list of all patients who are on intravenous antibiotics for more than 48 hours and are therefore potential candidates for an IV-to-PO switch. The consulting infectious diseases physician can review these patients' charts and contact the attending physician to investigate whether the patient can indeed be switched to oral therapy. Electronic drug-ordering systems might be a more convenient way to streamline antibiotic prescribing methods.

In 1999, Teich et al reported on their study of a computer program to facilitate switch therapy. They found that physicians agreed to change (or had just changed) the patient's medication from intravenous to oral in 31.7% of cases.³⁵

SPECIAL CONCERNS

Section 10 of 11  

• Authors and Editors
• Introduction
• Antibiotics
• Antipsychotics
• Analgesics
• Antivirals
• Medication
• Inpatient Care
• Implementation of Switch Therapy Protocol
• Special Concerns
• References

According to Wilcox, less obvious potential benefits of sequential antimicrobial therapy include fewer intravascular catheter infections because of shorter line-dwell times and less endoluminal contamination.³⁶ Sequential antimicrobial therapy may also be used as part of a policy to reduce the selective pressure, particularly due to cephalosporin use, for endemic hospital pathogens such as C difficile and extended-spectrum–producing gram-negative bacilli.

Caceres et al found that an in-hospital observation period after a patient is changed to oral treatment is of limited usefulness. In this study, only 1% of patients had evidence of clinical relapse within the study period. Four percent of patients had adverse reactions to their oral antibiotic, none of which was serious. Thus, discharging patients after changing to oral antibiotics could result in savings from avoiding an extra day of hospitalization, amounting to millions of dollars annually in the United States.³⁷

REFERENCES

Section 11 of 11

• Authors and Editors
• Introduction
• Antibiotics
• Antipsychotics
• Analgesics
• Antivirals
• Medication
• Inpatient Care
• Implementation of Switch Therapy Protocol
• Special Concerns
• References

1. Nathan RV, Rhew DC, Murray C, Bratzler DW, Houck PM, Weingarten SR. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med. Jun 2006;119(6):512.e1-7. [Medline].
2. Siegel RE. Strategies for early discharge of the hospitalized patient with community-acquired pneumonia. Clin Chest Med. Sep 1999;20(3):599-605. [Medline].
3. Ramírez JA; Community-Acquired Pneumonia Organization Investigators. Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study. Semin Respir Crit Care Med. Dec 2005;26(6):543-52. [Medline].
4. Rifkin WD, Conner D, Silver A, Eichorn A. Comparison of processes and outcomes of pneumonia care between hospitals and community-based primary care physicians. Mayo Clin Proc. Oct 2002;77(10):1053-8. [Medline].
5. Wawruch M, Bozekova L, Krcmery S, et al. Cost-effectiveness analysis of switching from intravenous to oral administration of antibiotics in elderly patients. Bratisl Lek Listy. 2004;105(10-11):374-8. [Medline].
6. Oosterheert JJ, Bonten MJ, Schneider MM, Buskens E, Lammers JW, Hustinx WM. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ. Epub 2006 Nov 7;333(7580):1193. [Medline].
7. Peyrani P, Christensen D, LaJoie AS, Nakamatsu R, Arnold F, Schulz P, et al. Antibiotic therapy of hospitalized patients with community-acquired pneumonia: an international perspective from the CAPO Cohort Study.J Ky Med Assoc. 2006 Nov;104(11):513-7. [Medline].
8. Rhew DC, Tu GS, Ofman J, et al. Early switch and early discharge strategies in patients with community- acquired pneumonia: a meta-analysis. Arch Intern Med. Mar 12 2001;161(5):722-7. [Medline].
9. Angeli P, Guarda S, Fasolato S, Miola E, Craighero R, Piccolo F. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther. Jan 1 2006;23(1):75-84. [Medline].
10. Cunha BA. Intravenous to oral antibiotic switch therapy. Drugs Today (Barc). May 2001;37(5):311-9. [Medline].
11. Vogtlander NP, Van Kasteren ME, Natsch S, et al. Improving the process of antibiotic therapy in daily practice: interventions to optimize timing, dosage adjustment to renal function, and switch therapy. Arch Intern Med. Jun 14 2004;164(11):1206-12. [Medline].
12. Pablos AI, Escobar I, Albinana S, et al. Evaluation of an antibiotic intravenous to oral sequential therapy program. Pharmacoepidemiol Drug Saf. Jan 2005;14(1):53-9. [Medline].
13. Giamarellou H, Bassaris HP, Petrikkos G, et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother. Dec 2000;44(12):3264-71. [Medline].
14. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg. Mar 1996;223(3):303-15. [Medline].
15. Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest. Aug 2003;124(2):526-35. [Medline].
16. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential IV and oral moxifloxacin compared with sequential IV and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother. Jun 2002;46(6):1746-54. [Medline].
17. Van den Brande P, Vondra V, Vogel F, et al. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. Chest. Aug 1997;112(2):406-15. [Medline].
18. Hamilton-Miller J. Cefixime for switch therapy. Chemotherapy. Sep 1998;44 Suppl 1:24-7. [Medline].
19. Dagan R, Syrogiannopoulos G, Ashkenazi S, et al. Parenteral-oral switch in the management of paediatric pneumonia. Drugs. 1994;47 Suppl 3:43-51. [Medline].
20. Fernandez P, San Martin L. [Community acquired pneumonia: from intravenous to oral cephalosporin sequential therapy]. Rev Med Chil. Mar 2000;128(3):267-72. [Medline].
21. Parola D, Dell'Orso D, Terzano C. [Efficacy and safety of clarithromycin in the treatment of community-acquired pneumonia]. Recenti Prog Med. Jan 2000;91(1):12-5. [Medline].
22. Martinez MJ, Freire A, Castro I, et al. Clinical and economic impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion. Pharm World Sci. Apr 2000;22(2):53-8. [Medline].
23. Tomera KM, Burdmann EA, Reyna OG, et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. Sep 2002;46(9):2895-900. [Medline].
24. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt). Spring 2003;4(1):57-70. [Medline].
25. Starakis I, Karravias D, Asimakopoulos C, et al. Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral)+metronidazole (intravenous/oral) with ceftriaxone (intravenous)+metronidazole (intravenous/oral) for the treatment of intra-abdominal infections. Int J Antimicrob Agents. Jan 2003;21(1):49-57. [Medline].
26. Gollin G, Abarbanell A, Moores D. Oral antibiotics in the management of perforated appendicitis in children. Am Surg. Dec 2002;68(12):1072-4. [Medline].
27. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. Aug 2002;46(8):2546-53. [Medline].
28. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation. Sep 15 2002;74(5):688-95. [Medline].
29. Kasper S, Muller-Spahn F. Intravenous antidepressant treatment: focus on citalopram. Eur Arch Psychiatry Clin Neurosci. Jun 2002;252(3):105-9. [Medline].
30. Adler L, Hajak G, Lehmann K, et al. On the problems of switching from intravenous to oral administration in drug treatment of endogenous depression--a placebo-controlled double- blind trial with doxepin. Pharmacopsychiatry. Mar 1997;30(2):62-9. [Medline].
31. Carcao MD, Lau RC, Gupta A, et al. Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised children. Pediatr Infect Dis J. Jul 1998;17(7):626-31. [Medline].
32. Halm EA, Switzer GE, Mittman BS, et al. What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia?. J Gen Intern Med. Sep 2001;16(9):599-605. [Medline].
33. Ramirez JA. Managing antiinfective therapy of community-acquired pneumonia in the hospital setting: focus on switch therapy. Pharmacotherapy. Jul 2001;21(7 Pt 2):79S-82S. [Medline].
34. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. Nov 8 1999;159(20):2449-54. [Medline].
35. Teich JM, Petronzio AM, Gerner JR, et al. An information system to promote intravenous-to-oral medication conversion. Proc AMIA Symp. 1999;415-9. [Medline].
36. Wilcox MH. Implementation of sequential therapy programs--a microbiologist's view. J Infect. Jul 1998;37 Suppl 1:51-4. [Medline].
37. Caceres VM, Stange KC, Kikano GE, Zyzanski SJ. The clinical utility of a day of hospital observation after switching from intravenous to oral antibiotic therapy in the treatment of pyelonephritis. J Fam Pract. Oct 1994;39(4):337-9.